VanEck Morningstar Global Wide Moat ETF (MOTG)
- Previous Close
35.11 - Open
35.42 - Bid 26.56 x 1000
- Ask 44.26 x 1000
- Day's Range
35.38 - 35.42 - 52 Week Range
30.25 - 36.70 - Volume
343 - Avg. Volume
1,782 - Net Assets 18.33M
- NAV 35.17
- PE Ratio (TTM) 20.21
- Yield 1.77%
- YTD Daily Total Return 0.29%
- Beta (5Y Monthly) 1.01
- Expense Ratio (net) 0.52%
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index is comprised of securities issued by companies that Morningstar, Inc. determines to have sustainable competitive advantages based on a proprietary methodology that considers quantitative and qualitative factors ("wide moat companies").
VanEck
Fund Family
Global Large-Stock Blend
Fund Category
18.33M
Net Assets
2018-10-30
Inception Date
Performance Overview: MOTG
Trailing returns as of 4/25/2024. Category is Global Large-Stock Blend.
People Also Watch
Holdings: MOTG
Top 10 Holdings (21.70% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MOTG
Analyst Report: Accenture plc
Accenture is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
RatingPrice TargetAnalyst Report: IQVIA Holdings Inc
IQVIA Holdings is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company is the result of the 2016 merger of Quintiles Transnational, a contract research organization, and IMS Health, a healthcare data and analytics provider. IQVIA is headquartered in Research Triangle Park, North Carolina. IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
RatingPrice TargetAnalyst Report: IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
RatingPrice TargetAnalyst Report: Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target